Patents Assigned to Dexcel Ltd.
-
Patent number: 10945960Abstract: Provided herein is a celecoxib and amlodipine composition and method of making the same. The composition contains granules containing celecoxib. The amlodipine is incorporated into the composition as an extragranulate.Type: GrantFiled: May 31, 2019Date of Patent: March 16, 2021Assignees: Dexcel Ltd., Kitov PharmaceuticalsInventor: Yitshak Itsik Efrati
-
Patent number: 10925835Abstract: Provided herein is a celecoxib and amlodipine composition and method of making the same. The composition contains granules containing celecoxib. The amlodipine is incorporated into the composition as an extragranulate.Type: GrantFiled: August 31, 2020Date of Patent: February 23, 2021Assignees: DEXCEL LTD., KITOV PHARMACEUTICALSInventor: Yitshak Itsik Efrati
-
Patent number: 10350171Abstract: Provided herein is a celecoxib and amlodipine composition and method of making the same. The composition contains granules containing celecoxib. The amlodipine is incorporated into the composition as an extragranulate.Type: GrantFiled: June 14, 2018Date of Patent: July 16, 2019Assignees: Dexcel Ltd., Kitov PharmaceuticalsInventor: Yitshak Itsik Efrati
-
Publication number: 20160113878Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.Type: ApplicationFiled: January 6, 2016Publication date: April 28, 2016Applicant: DEXCEL LTD.Inventors: Raffael Lahav, Valerie Azoulay
-
Patent number: 9023391Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.Type: GrantFiled: April 17, 2007Date of Patent: May 5, 2015Assignee: Dexcel Ltd.Inventors: Valerie Azoulay, Erica Lahav
-
Patent number: 8105627Abstract: An extended release formulation for administration of venlafaxine in an oral tablet dosage form. The formulation preferably features a core, over which an outer coating is layered. The core preferably contains venlafaxine, a filler, and a water soluble cellulosic polymer, optionally and more preferably with a water insoluble cellulosic polymer. The core is preferably coated with a coating material. The coating preferably contains a mixture of water soluble cellulosic polymer and a water insoluble cellulosic polymer. According to a first embodiment of the present invention, the filler is preferably present in an amount of at least about 40% weight per weight of the total formulation. More preferably, the filler comprises microcrystalline cellulose. Most preferably, the filler solely comprises microcrystalline cellulose. Also most preferably, microcrystalline cellulose is present in the core in a range of from about 45% to about 65% weight per weight of the total formulation.Type: GrantFiled: December 11, 2003Date of Patent: January 31, 2012Assignee: Dexcel Ltd.Inventors: Sima Volpert, Avi Avramoff
-
Publication number: 20100278909Abstract: A method for producing granules of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, which comprises: a) mixing the angiotensin II receptor antagonist or pharmaceutically acceptable salt thereof with a melt granulating agent to form a mixture; b) elevating the temperature of the mixture to the melting point of the melt granulating agent to form a solid dispersion of the angiotensin II receptor antagonist in the melt granulating agent; and c) cooling the solid dispersion to form granules; wherein the melt granulating agent is the only granulating agent used to form the granules.Type: ApplicationFiled: May 29, 2008Publication date: November 4, 2010Applicant: DEXCEL LTD.Inventors: Ron Schlinger, Avi Avramoff
-
Patent number: 7732404Abstract: A novel cyclosporine formulation, which is a pro-nanodispersion at room temperature, featuring solid particles of a relatively large particle size (at least about 150 nm) and yet which is a nanodispersion at body temperature.Type: GrantFiled: February 28, 2006Date of Patent: June 8, 2010Assignee: Dexcel LtdInventors: Abraham J. Domb, Avi Avramoff, Victor Pevzner
-
Publication number: 20070196485Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.Type: ApplicationFiled: April 17, 2007Publication date: August 23, 2007Applicant: DEXCEL LTD.Inventors: Raffael Lahav, Erica Lahav, Valerie Azoulay
-
Patent number: 7255878Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.Type: GrantFiled: June 21, 2000Date of Patent: August 14, 2007Assignee: Dexcel Ltd.Inventors: Erica Lahav, legal representative, Valerie Azoulay, Raffael Lahav, deceased
-
Patent number: 7026290Abstract: A formulation for the administration of a cyclosporin. This formulation features a hydrophilic solvent which is characterized by being a lower alkyl ester of hydroxyalkanoic acid; and a surfactant, preferably a combination of a surfactant with a high HLB (hydrophilic/lipophilic balance) of at least about 8 and a surfactant with a low HLB of less than about 5. Other ingredients are optional, such as a fatty acid ester such as tricaprin, a phospholipid, and an ethoxylated fat such as Cremophor or another similar substance. Optionally, the ethoxylated fat is substituted for the surfactant. The preferred particle size of the resultant formulation is less than about 100 nm, more preferably less than about 60 nm, and most preferably from about 5 nm to about 50 nm. The formulation of the present invention is characterized by having high bioavailability.Type: GrantFiled: December 30, 1999Date of Patent: April 11, 2006Assignee: Dexcel Ltd.Inventor: Abraham J. Domb